Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy

Human Gene Therapy

Volumn 22, Issue 12, 2011, Pages 1499-1509

  Bish, Lawrence T ^a   Sleeper, Meg M ^b   Forbes, Sean C ^c   Morine, Kevin J ^a   Reynolds, Caryn ^b   Singletary, Gretchen E ^b   Trafny, Dennis ^b   Pham, Jennifer ^a   Bogan, Janet ^d   Kornegay, Joe N ^d   Vandenborne, Krista ^c   Walter, Glenn A ^c   Sweeney, H Lee ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOSTATIN;

ADENO ASSOCIATED VIRUS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DUCHENNE MUSCULAR DYSTROPHY; EUTHANASIA; GENE TRANSFER; HUMAN; MUSCLE CELL; MUSCLE MASS; MYOFIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN SYNTHESIS INHIBITION; SKELETAL MUSCLE; SURGICAL TECHNIQUE;

ANIMALS; BLOTTING, WESTERN; CREATINE KINASE; DEPENDOVIRUS; DOGS; FIBROSIS; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; LIVER; MAGNETIC RESONANCE IMAGING; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MYOSTATIN; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT TRANSCRIPTION FACTORS;

EID: 81355134171     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.102     Document Type: Article

References (58)

1. Aartsma-Rus, A., Van Deutekom, J.C., Fokkema, I.F., et al. (2006). Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34, 135-144. (Pubitemid 44167796)
2. Bartoli, M., Poupiot, J., Vulin, A., et al. (2007). AAV-mediated delivery of a mutated myostatin propeptide ameliorates cal-pain 3 but not a-sarcoglycan deficiency. Gene Ther. 14, 733-740. (Pubitemid 46585654)
3. Barton, E.R., Morris, L., Musaro, A., et al. (2002). Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell Biol. 157, 137-148.
4. Bell, P., Gao, G., Haskins, M.E., et al. (2011). Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. Hum. Gene Ther. [Epub ahead of print].
5. Bogdanovich, S., Krag, T.O., Barton, E.R., et al. (2002). Functional improvement of dystrophic muscle by myostatin blockade. Nature 420, 418-421. (Pubitemid 35415652)
6. Bogdanovich, S., Perkins, K.J., Krag, T.O., et al. (2005). Myostatin propeptide-mediated amelioration of dystrophic pathophysi-ology. FASEB J. 19, 543-549. (Pubitemid 40471245)
7. Bogdanovich, S., McNally, E.M., and Khurana, T.S. (2008). Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve 37, 308-316. (Pubitemid 351304790)
8. Cohn, R.D., Liang, H.Y., Shetty, R., et al. (2007). Myostatin does not regulate cardiac hypertrophy or fibrosis. Neuromuscul. Disord. 17, 290-296. (Pubitemid 46528706)
9. Denti, M.A., Rosa, A., D'Antona, G., et al. (2006). Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc. Natl. Acad. Sci. U.S.A. 103, 3758-3763. (Pubitemid 43376628)
10. Denti, M.A., Incitti, T., Sthandier, O., et al. (2008). Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum. Gene Ther. 19, 601-608. (Pubitemid 351913531)
11. Emery, A.E. (2002). The muscular dystrophies. Lancet 359, 687-695. (Pubitemid 34203773)
12. Finkel, R.S. (2010). Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J. Child Neurol. 25, 1158-1164.
13. Foley, J.M., Jayaraman, R.C., Prior, B.M., et al. (1999). MR measurements of muscle damage and adaptation after eccentric exercise. J. Appl. Physiol. 87, 2311-2318.
14. Goyenvalle, A., Vulin, A., Fougerousse, F., et al. (2004). Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306, 1796-1799. (Pubitemid 39601401)
15. Gregorevic, P., Blankinship, M.J., Allen, J.M., et al. (2004). Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10, 828-834. (Pubitemid 39070856)
16. Harper, S.Q., Hauser, M.A., DelloRusso, C., et al. (2002). Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253-261. (Pubitemid 34250103)
17. Herzog, R.W., Yang, E.Y., Couto, L.B., et al. (1999). Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 5, 56-63. (Pubitemid 29050999)
18. Kambadur, R., Sharma, M., Smith, T.P., and Bass, J.J. (1997). Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res. 7, 910-916. (Pubitemid 27445377)
19. Kan, H.E., Scheenen, T.W., Wohlgemuth, M., et al. (2009). Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul. Disord. 19, 357-362.
20. Kornegay, J.N., Li, J., Bogan, J.R., et al. (2010). Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol. Ther. 18, 1501-1508.
21. Kota, J., Handy, C.R., Haidet, A.M., et al. (2009). Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci. Transl. Med. 1, 6ra15.
22. Lee, S.J. (2004). Regulation of muscle mass by myostatin. Annu. Rev. Cell Dev. Biol. 20, 61-86.
23. Lee, S.J. (2007a). Quadrupling muscle mass in mice by targeting TGF-b signaling pathways. PLoS One 2, e789.
24. Lee, S.J. (2007b). Sprinting without myostatin: a genetic determinant of athletic prowess. Trends Genet. 23, 475-477.
25. Lee, S.J., Reed, L.A., Davies, M.V., et al. (2005). Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. U.S.A. 102, 18117-18122. (Pubitemid 41798511)
26. Li, Z.B., Kollias, H.D., and Wagner, K.R. (2008). Myostatin directly regulates skeletal muscle fibrosis. J. Biol. Chem. 283, 19371-19378.
27. Liu, M., Yue, Y., Harper, S.Q., et al. (2005). Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol. Ther. 11, 245-256.
28. Loganathan, R., Bilgen, M., Al-Hafez, B., and Smirnova, I.V. (2006). Characterization of alterations in diabetic myocardial tissue using high resolution MRI. Int. J. Cardiovasc. Imaging 22, 81-90. (Pubitemid 43372356)
29. Mathur, S., Vohra, R.S., Germain, S.A., et al. (2011). Changes in muscle T2 and tissue damage after downhill running in mdx mice. Muscle Nerve 43, 878-886.
30. McCarty, D.M., Monahan, P.E., and Samulski, R.J. (2001). Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8, 1248-1254. (Pubitemid 32780813)
31. McPherron, A.C., Lawler, A.M., and Lee, S.J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-b superfamily member. Nature 387, 83-90. (Pubitemid 27202654)
32. Mendias, C.L., Marcin, J.E., Calerdon, D.R., and Faulkner, J.A. (2006). Contractile properties of EDL and soleus muscles of myostatin-deficient mice. J. Appl. Physiol. 101, 898-905. (Pubitemid 44352306)
33. Mingozzi, F., Hasbrouck, N.C., Basner-Tschakarjan, E., et al. (2007). Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110, 2334-2341. (Pubitemid 47523153)
34. Miyagoe-Suzuki, Y., and Takeda, S. (2010). Gene therapy for muscle disease. Exp. Cell Res. 316, 3087-3092.
35. Morine, K.J., Bish, L.T., Pendrak, K., et al. (2010a). Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. PLoS One 5, e9176.
36. Morine, K.J., Bish, L.T., Selsby, J.T., et al. (2010b). Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle Nerve 42, 722-730.
37. Moulton, H.M., and Moulton, J.D. (2010). Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim. Biophys. Acta 1798, 2296-2303.
38. Muntoni, F., Torelli, S., and Ferlini, A. (2003). Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731-740. (Pubitemid 37443515)
39. Pacak, C.A., Walter, G.A., Gaidosh, G., et al. (2007). Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol. Ther. 15, 1775-1781. (Pubitemid 47434183)
40. Pacak, C.A., Conlon, T., Mah, C.S., and Byrne, B.J. (2008). Relative persistence of AAV serotype 1 vector genomes in dystrophic muscle. Genet. Vaccines Ther. 6, 14.
41. Partridge, T. (2010). The potential of exon skipping for treatment for Duchenne muscular dystrophy. J. Child Neurol. 25, 1165-1170.
42. Pistilli, E.E., Bogdanovich, S., Goncalves, M.D., et al. (2011). Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am. J. Pathol. 178, 1287-1297.
43. Qiao, C., Li, J., Jiang, J., et al. (2008). Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum. Gene Ther. 19, 241-254.
44. Qiao, C., Li, J., Zheng, H., et al. (2009). Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum. Gene Ther. 20, 1-10.
45. Rodino-Klapac, L.R., Montgomery, C.L., Bremer, W.G., et al. (2010). Persistent expression of FLAG-tagged micro dystro-phin in nonhuman primates following intramuscular and vascular delivery. Mol. Ther. 18, 109-117.
46. Schuelke, M., Wagner, K.R., Stolz, L.E., et al. (2004). Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 350, 2682-2688. (Pubitemid 38788003)
47. Sharp, N.J., Kornegay, J.N., Van Camp, S.D., et al. (1992). An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13, 115-121.
48. Shimatsu, Y., Katagiri, K., Furuta, T., et al. (2003). Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp. Anim. 52, 93-97. (Pubitemid 41349972)
49. Sicinski, P., Geng, Y., Ryder-Cook, A.S., et al. (1989). The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244, 1578-1580. (Pubitemid 19189735)
50. Tyler, K.L. (2003). Origins and early descriptions of "Duchenne muscular dystrophy." Muscle Nerve 28, 402-422. (Pubitemid 37193768)
51. Valentine, B.A., Cooper, B.J., de Lahunta, A., et al. (1988). Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J. Neurol. Sci. 88, 69-81. (Pubitemid 19016584)
52. Wagner, K.R., McPherron, A.C., Winik, N., and Lee, S.J. (2002). Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann. Neurol. 52, 832-836. (Pubitemid 35403195)
53. Wagner, K.R., Fleckenstein, J.L., Amato, A.A., et al. (2008). A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol. 63, 561-571.
54. Walmsley, G.L., Arechavala-Gomeza, V., Fernandez-Fuente, M., et al. (2010). A Duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient Cavalier King Charles Spaniels is amenable to exon 51 skipping. PLoS One 5, e8647.
55. Wang, Z., Kuhr, C.S., Allen, J.M., et al. (2007). Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immu-nosuppression. Mol. Ther. 15, 1160-1166. (Pubitemid 46813619)
56. Wang, Z., Chamberlain, J.S., Tapscott, S.J., and Storb, R. (2009). Gene therapy in large animal models of muscular dystrophy. ILAR J. 50, 187-198.
57. Wolfman, N.M., McPherron, A.C., Pappano, W.N., et al. (2003). Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc. Natl. Acad. Sci. U.S.A. 100, 15842-15846. (Pubitemid 38021077)
58. Yokota, T., Lu, Q.L., Partridge, T., et al. (2009). Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann. Neurol. 65, 667-676.